Parenterale formuleringer af peptide til behandling af systemisk lupus erythematosus
The subject invention provides a pharmaceutical composition comprising: an aqueous carrier; from 0.1 mg/ml to 20 mg/ml of a pharmaceutically acceptable salt of a) a peptide comprising at least 12 and at most 30 consecutive amino acids, b) a peptide comprising consecutive amino acids having the seque...
Saved in:
Main Authors | , , , , |
---|---|
Format | Patent |
Language | Danish |
Published |
02.01.2017
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The subject invention provides a pharmaceutical composition comprising: an aqueous carrier; from 0.1 mg/ml to 20 mg/ml of a pharmaceutically acceptable salt of a) a peptide comprising at least 12 and at most 30 consecutive amino acids, b) a peptide comprising consecutive amino acids having the sequence shown by any of SEQ ID NOS. 8-17, c) a peptide comprising consecutive amino acids having a sequence of any of a) and b), or at least two sequences in (a), or d) a peptide comprising consecutive amino acids having a sequence comprising at least two identical sequences included in (a); and a solubility enhancer; and wherein the composition has a pH between 4 and 9, and a method of alleviating symptoms of SLE in a human by administering an effective amount of the composition. |
---|---|
Bibliography: | Application Number: DK20040702215T |